Alpine Immune Sciences To Present New Translational Data On Povetacicept And Acazicolcept In Systemic Lupus Erythematosus At American College Of Rheumatology Convergence 2023
Portfolio Pulse from Benzinga Newsdesk
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced it will present new translational data for povetacicept and acazicolcept in systemic lupus erythematosus at the American College of Rheumatology Convergence 2023. The data will be presented on November 14 and November 12, 2023, respectively. Both drugs are being developed for the treatment of autoimmune diseases, with povetacicept targeting BAFF and APRIL cytokines, and acazicolcept inhibiting the CD28 and ICOS T-cell costimulatory pathways.
October 30, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alpine Immune Sciences will present new data on povetacicept and acazicolcept, drugs being developed for autoimmune diseases, at a major conference. This could potentially increase investor interest in the company.
Presenting new data at a major conference can increase visibility and potentially attract investor interest. The development of new drugs for autoimmune diseases could also have a positive impact on the company's future revenues if the drugs are successful.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100